Table 3.
Characteristics of the formulation of QT/Blank-SLNs.
| Formulation | Drug-Lipid Ratio | Particle Size | PDI | Zeta Potential (mV) |
|---|---|---|---|---|
| QT-SLN1 | 1:1 | 45.5 ± 3.5 | 0.112 ± 0.01 | −1.8 ± 0.26 |
| Blank-SLN1 | - | 45.1 ± 3.2 | 0.114 ± 0.02 | −1.1 ± 0.35 |
| QT-SLN2 | 1:3 | 48.4 ± 3.9 | 0.118 ± 0.07 | −5.5 ± 1.12 |
| Blank-SLN2 | - | 47.9 ± 4.1 | 0.123 ± 0.06 | −8.9 ± 1.33 |
| QT-SLN3 | 1:5 | 58.3 ± 4.8 | 0.135 ± 0.07 | −12.6 ± 2.32 |
| Blank-SLN3 | - | 56.1 ± 4.6 | 0.127 ± 0.06 | −13.9 ± 1.87 |
| QT-SLN4 | 1:10 | 85.5 ± 8.5 | 0.152 ± 0.04 | −22.5 ± 0.6 |
| Blank-SLN4 | - | 84.7 ± 8.1 | 0.161 ± 0.05 | −23.6 ± 0.5 |
| QT-SLN5 | 1:15 | 99.6 ± 9.1 | 0.342 ± 0.04 | −18.9 ± 3.13 |
| Blank-SLN5 | - | 98.8 ± 8.7 | 0.316 ± 0.11 | −20.3 ± 2.58 |
Results are given as mean ± SD (n = 3). SD: standard deviation, PDI: polydispersity index.